These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10146961)

  • 1. Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
    Bergemann R; Brandt A; Siegrist W
    Pharmacoeconomics; 1993 Feb; 3(2):131-9. PubMed ID: 10146961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
    Polakowska M; Broda G; Rywik S; Piotrowski W; Bednarska M; Kuźmińska A; Pytlak A; Chotkowska E
    Pol Arch Med Wewn; 1994 Jan; 91(1):9-18. PubMed ID: 8190659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.
    Kremer P; Marowski C; Jones C; Acacia E
    Curr Med Res Opin; 1989; 11(5):293-303. PubMed ID: 2702851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
    Kirchgässler KU; Schiffner-Rohe J; Stahlheber U
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):237-46. PubMed ID: 10173126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia.
    Lavezzari M; Milanesi G; Oggioni E; Pamparana F
    J Int Med Res; 1989; 17(4):373-80. PubMed ID: 2676653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
    Julius U; Hora C; Gross P; Fücker K; Bergmann S; Hanefeld M
    Fortschr Med; 1992 Dec; 110(35-36):669-72. PubMed ID: 1487226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
    Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W
    Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia].
    Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J
    Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.